Want to see EOLS full AI Analyst Report?
EOLS Stock Chart & Stats
$5.98
$0.20(3.34%)
At close: 4:00 PM EDT
$5.98
$0.20(3.34%)
Day’s Range― - ―
52-Week Range$3.86 - $8.69
Previous Close$6.18
Volume650.24K
Average Volume (3M)756.56K
Market Cap
$551.52M
Enterprise Value$577.18
Total Cash (Recent Filing)$45.17M
Total Debt (Recent Filing)$164.80M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Nov 10, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding66,050,440
10 Day Avg. Volume763,153
30 Day Avg. Volume756,558
Financial Highlights & Ratios
PEG Ratio6.73
Price to Book (P/B)-18.55
Price to Sales (P/S)1.44
P/FCF Ratio-8.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.00Price Target Upside150.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$333.84M
Bulls Say, Bears Say
Bulls Say
Revenue Scale And Gross MarginsRevenue has grown from $99.7M in 2021 to $316.5M TTM, while gross margin remains about 67%. This indicates meaningful commercial scale and strong product economics that can support future operating leverage.
Portfolio And International ExpansionAdding Estyme markets and expanding Evolysse internationally broadens Evolus beyond its core toxin product. A wider portfolio can improve customer retention, increase practice wallet share and create additional long-term growth avenues.
Improving Profitability And GuidanceSustained positive adjusted EBITDA and higher revenue and margin guidance suggest improving operating leverage. If execution continues, rising scale could help convert strong gross margins into durable operating profitability.
Bears Say
Negative Equity And Rising DebtNegative equity and steadily rising debt constrain financial flexibility and increase dependence on financing. This weak capitalization leaves less room to absorb execution setbacks or fund expansion without added financial pressure.
Persistent Cash BurnThe core business continues to consume cash despite narrowing losses and improving EBITDA. Until operating cash flow becomes consistently positive, Evolus may need credit facilities or other financing to support investment and ongoing operations.
Toxin Revenue ConcentrationMost revenue remains tied to the toxin category, leaving the company exposed to competitive, product-specific and market-demand risks. New products are gaining traction, but diversification is not yet sufficient to materially reduce concentration.
Evolus News
EOLS FAQ
What was Evolus, Inc.’s price range in the past 12 months?
Evolus, Inc. lowest stock price was $3.86 and its highest was $8.69 in the past 12 months.
What is Evolus, Inc.’s market cap?
Evolus, Inc.’s market cap is $551.52M.
When is Evolus, Inc.’s upcoming earnings report date?
Evolus, Inc.’s upcoming earnings report date is Nov 10, 2026 which is in 80 days.
How were Evolus, Inc.’s earnings last quarter?
Evolus, Inc. released its earnings results on Aug 05, 2026. The company reported $0.007 earnings per share for the quarter, beating the consensus estimate of -$0.033 by $0.04.
Is Evolus, Inc. overvalued?
According to Wall Street analysts Evolus, Inc.’s price is currently Undervalued.
Does Evolus, Inc. pay dividends?
Evolus, Inc. does not currently pay dividends.
What is Evolus, Inc.’s EPS estimate?
Evolus, Inc.’s EPS estimate is -0.07.
How many shares outstanding does Evolus, Inc. have?
Evolus, Inc. has 66,050,440 shares outstanding.
What happened to Evolus, Inc.’s price movement after its last earnings report?
Evolus, Inc. reported an EPS of $0.007 in its last earnings report, beating expectations of -$0.033. Following the earnings report the stock price went up 19.903%.
Which hedge fund is a major shareholder of Evolus, Inc.?
Currently, no hedge funds are holding shares in EOLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (150.84% Upside)
$15.00 (150.84% Upside)
Blogger Sentiment
Bullish
EOLS Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.1%
Last 30 Days ▲ 44.3%
Last 30 Days ▲ 44.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
8.40%
Trailing 12-Months
Company Description
Evolus, Inc.
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
EOLS Company Deck
EOLS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated clear operational momentum: double-digit top-line growth (21% in Q2, 14% year-to-date), third consecutive quarter of positive adjusted EBITDA, expanded international presence, new strategic licensing (ProFuelo) and an upwardly revised full-year revenue and margin outlook. These positives were tempered by sequential increases in operating expenses, modest absolute adjusted EBITDA, a decline in cash versus the prior quarter and ongoing tariff uncertainty that requires inventory repositioning. Given the company’s raised guidance, profitable growth trajectory, and strategic partnerships that expand the product portfolio, the highlights materially outweigh the lowlights.View all EOLS earnings summariesEOLS Stock 12 Month Forecast
Average Price Target
$15.00
▲(150.84% Upside)
Technical Analysis
Emergent Biosolutions
―
Rockwell Med
―
Organogenesis Holdings
―
Aquestive Therapeutics
―
Journey Medical Corp
―
Ownership Overview
3.12% Insiders
7.94% Mutual Funds
38.47% Other Institutional Investors
38.38% Public Companies and
Individual Investors